BioLife Solutions Announces $73 Million Sale of SciSafe
In a significant move aimed at reinforcing its strategic direction, BioLife Solutions, Inc. (NASDAQ: BLFS), a prominent player in the development and supply of cell processing tools and services for the cell and gene therapy market, has announced the sale of its biostorage subsidiary, SciSafe Holdings, Inc. The transaction, valued at $73 million, will be completed entirely in cash, marking a pivotal point in the company's ongoing evolution.
Impact of the Sale on BioLife Solutions
This sale is not just a financial transaction; it represents a major shift in BioLife's focus towards its proprietary, higher-margin consumable solutions, moving away from non-core businesses. Roderick de Greef, Chairman and CEO, emphasized the importance of this transition, stating, "This divestiture marks another major step forward in our strategic refocus on our proprietary, higher-margin, recurring-revenue consumable solutions and away from non-core products and services." With this sale, BioLife aims to bolster its financial standing and concentrate on developing innovative offerings essential for the growth of the cell and gene therapy market.
Performance of SciSafe Prior to Sale
SciSafe, which generated roughly $10.4 million in revenue over the six months leading up to the sale, has been a key player in BioLife's portfolio. Originally acquired in October 2020 for $39 million inclusive of earnout payments, the substantial sale price highlights the improvement in its valuation since acquisition. This transaction not only reflects positively on BioLife's management strategies but also provides a significant influx of capital to support its core operations and future innovations.
Changes in Management Structure
Additionally, the completion of this transaction has prompted organizational changes within BioLife Solutions. Todd Berard, currently the Chief Marketing Officer, will take on an expanded role as Chief Commercial Officer, overseeing all sales and marketing operations. Known for his over ten years of service at BioLife, Berard’s leadership is expected to drive the company’s growth in its core initiatives.
Furthermore, Garrie Richardson, BioLife's former Chief Revenue Officer, is set to become CEO of the now independent SciSafe. De Greef recognized Richardson's contributions since the acquisition and expressed gratitude for his efforts, wishing him and the SciSafe team continued success in their future endeavors.
Strategic Advisors in the Transaction
BioLife Solutions was guided through this pivotal sale by Stephens Inc. as its financial advisor, together with K&L Gates LLP providing legal counsel. Their expertise was instrumental in facilitating this significant milestone for the company.
About BioLife Solutions
BioLife Solutions continues to be a leading supplier in the CGT market, delivering vital cell processing tools and services. The company's technology supports the development of new therapies by ensuring the health and viability of biologic materials throughout their lifecycle, including collection, storage, and distribution. As BioLife advances its mission, it remains committed to innovative excellence and leadership in the industry.
Frequently Asked Questions
What prompted BioLife Solutions to sell SciSafe?
BioLife Solutions aimed to refocus on higher-margin cell processing products and enhance its financial position through this strategic divestiture.
How much revenue did SciSafe generate before the sale?
SciSafe generated approximately $10.4 million in revenue over a six-month period prior to the sale.
Who will take over management roles after the sale?
Todd Berard will assume the role of Chief Commercial Officer, while Garrie Richardson will become CEO of SciSafe.
What financial advisory firms assisted BioLife in this transaction?
Stephens Inc. served as the financial advisor, while K&L Gates LLP acted as legal counsel for the transaction.
What is the significance of this transaction for BioLife Solutions?
This sale provides BioLife with critical capital to invest in its core operations, aiding in the commercialization of innovative therapies in the CGT market.
